预约演示
更新于：2025-01-26
Alendronate Sodium
阿仑膦酸钠
更新于：2025-01-26
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 意大利 (1993-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C4H15NNaO8P2 |
InChIKeyHZMNHMQPEYMSTG-UHFFFAOYSA-N |
CAS号121268-17-5 |
关联
217
项与 阿仑膦酸钠 相关的临床试验NCT06016634
A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
IRCT20241108063637N1
The effect of alendronate treatment on iPTH levels in elderlies with age-related osteoporosis: a clinical trial study
CTR20243428
中国健康受试者空腹状态下单次口服阿仑膦酸钠片的单中心、开放、随机、两制剂、两序列、四周期、完全重复交叉人体生物等效性预试验
100 项与 阿仑膦酸钠 相关的临床结果
登录后查看更多信息
100 项与 阿仑膦酸钠 相关的转化医学
登录后查看更多信息
100 项与 阿仑膦酸钠 相关的专利（医药）
登录后查看更多信息
6,957
项与 阿仑膦酸钠 相关的文献（医药）2025-05-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
In silico evaluation of bisphosphonates identifies leading candidates for SARS-CoV-2 RdRp inhibition
Article
作者: Garg, Mohit ; Vasan, Seshadri S ; Sankaranarayanan, Murugesan ; Muzaffar-Ur-Rehman, Mohammed ; Chandu, Ala ; Kuthe, Pranali Vijaykumar ; Chougule, Kishor Suryakant
The novel coronavirus disease (COVID-19) pandemic has resulted in 777 million confirmed cases and over 7 million deaths worldwide, with insufficient treatment options. Innumerable efforts are being made around the world for faster identification of therapeutic agents to treat the deadly disease. Post Acute Sequelae of SARS-CoV-2 infection or COVID-19 (PASC), also called Long COVID, is still being understood and lacks treatment options as well. A growing list of drugs are being suggested by various in silico, in vitro and ex vivo models, however currently only two treatment options are widely used: the RNA-dependent RNA polymerase (RdRp) inhibitor remdesivir, and the main protease inhibitor nirmatrelvir in combination with ritonavir. Computational drug development tools and in silico studies involving molecular docking, molecular dynamics, entropy calculations and pharmacokinetics can be useful to identify new targets to treat COVID-19 and PASC, as shown in this work and our recent paper that identified alendronate as a promising candidate. In this study, we have investigated all bisphosphonates (BPs) on the ChEMBL database which can bind competitively to nidovirus RdRp-associated nucleotidyl (NiRAN) transferase domain, and systematically down selected seven candidates (CHEMBL608526, CHEMBL196676, CHEMBL164344, CHEMBL4291724, CHEMBL4569308, CHEMBL387132, CHEMBL98211), two of which closely resemble the approved drugs minodronate and zoledronate. This work and our recent paper together provide an in silico mechanistic explanation for alendronate and zoledronate users having dramatically reduced odds of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations, and indicate that similar observational studies in Japan with minodronate could be valuable.
2025-02-01Biomaterials advances
Carboxymethyl chitosan/alendronate sodium/Sr2+ modified TiO2 nanotube arrays enhancing osteogenic activity and antibacterial property
Article
作者: Liu, Tingting ; Jia, Kunpeng ; Ji, Yan ; Ma, Wenfu ; Chen, Jie ; Zuo, Changpeng ; Wang, Lingtao ; Pan, Changjiang ; Xu, Yan ; Zhang, Qiuyang
Titanium and its alloys are widely used as orthopedic implants owing to their good mechanical properties and excellent corrosion resistance. However, the insufficient osteogenic activity and antibacterial properties hinder their clinical applications. To address these issues, TiO2 nanotube arrays (TNT) were first fabricated on the TA2 alloy surface via an anodizing technique, and strontium ions (Sr2+) were then loaded by hydrothermal reaction (TNT + Sr) and annealing treatment (TNT + A). Subsequently, the polydopamine layer (TNT + PDA) was constructed to immobilize the carboxymethyl chitosan and alendronate sodium (TNT + CA) mixture. The prepared coatings were thoroughly characterized by scanning electron microscopy (SEM), energy dispersive spectrometer (EDS), X-ray photoelectron spectrometer (XPS), attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR), X-ray diffractometer (XRD), and water contact angle measurement. The results confirmed that Sr2+ ions, polydopamine, and carboxymethyl chitosan/alendronate sodium were successfully immobilized on the nanotubes. The coating of TNT + CA significantly enhanced the hydrophilicity, and effectively delayed the release of Sr2+ and alendronate. The TNT + CA coating significantly promoted osteoblast adhesion and proliferation, and up-regulated the expressions of alkaline phosphatase (ALP), osteocalcin (OCN), and osteoblast-specific transcription factor (RUNX2). TNT + CA was able to rapidly induce in situ hydroxyapatite deposition from the simulated body fluid (SBF). Moreover, TNT + CA coating showed inhibition against Escherichia coli and Staphylococcus aureus (especially against Escherichia coli). The prepared TNT + CA coating provides a novel strategy for enhancing bone affinity, improving osteoblast behaviors, and antibacterial properties of titanium-based biomaterials.
2025-02-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Design and evaluation of a multi-responsive dual-modality bone-targeted drug delivery vehicle for the treatment of osteosarcoma
Article
作者: Huang, Huilian ; Asghar, Sajid ; Yuan, Chenjun ; Sang, Muhui ; Lin, Ling ; Chen, Su ; Xiao, Yanyu
The combination of chemotherapy and photothermal therapy not only improves the therapeutic effect but also limits the side effects of drugs. Herein, a multi-responsive dual-modality bone-targeted drug delivery vehicle for the treatment of osteosarcoma was designed by utilizing alendronate sodium as a bone-targeting ligand for the targeted delivery of doxorubicin (DOX) loaded polydopamine nanoparticles (PDA NPs) coated with γ-polyglutamic acid (APC@PDA/DOX NPs). The average size of spherical NPs was 140.0 nm with a zeta potential of -25.63 mV. The drug loading and encapsulation efficiency were 11.63 % and 96.44 %, respectively. The constructed NPs were responsive to acidic pH, redox conditions, and near-infrared light as the drug release rate of the system reached 70 %. Cell experiments showed that APC@PDA/DOX NPs significantly enhanced cytotoxicity in mouse K7M2 osteosarcoma cells due to PDA-induced hyperthermia and DOX-induced cytotoxicity. Compared with the free DOX solution, the area under the curve of APC@PDA/DOX NPs increased by 8.52 times, iterating the significantly prolonged circulation time of NPs in vivo that manifested in higher bioavailability. The biodistribution study showed that APC@PDA/DOX NPs enacted excellent bone targeting and tumor tissue localization. In general, APC@PDA/DOX NPs may offer a feasible and effective strategy for osteosarcoma-targeted therapy.
100 项与 阿仑膦酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨折 | 美国 | 2003-09-17 | |
| 骨质疏松性骨折 | 美国 | 2003-09-17 | |
| 糖皮质激素诱导的骨质疏松症 | 美国 | 1999-06-16 | |
| 畸形性骨炎 | 美国 | 1995-09-29 | |
| 绝经期后骨质疏松 | 美国 | 1995-09-29 | |
| 骨质疏松症 | 意大利 | 1993-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非转移性前列腺癌 | 临床3期 | - | 2005-07-01 | |
| 髋部骨折 | 临床3期 | 加拿大 | 2003-01-01 | |
| 糖尿病 | 临床2期 | 以色列 | 2016-04-01 | |
| 冠状动脉狭窄 | 临床2期 | 以色列 | 2008-09-01 | |
| 青少年骨质疏松症 | 临床2期 | 美国 | 2000-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 170 | Alendronate solution (ALN-S) | 壓獵繭憲鹽壓鏇衊繭蓋(淵構鬱鹹築遞鑰遞鹹齋) = 窪簾鹹壓範鹽襯醖憲遞 簾製遞觸壓鹽鏇夢齋遞 (遞餘顧鹹網積餘鬱艱選, 0.6) 更多 | 积极 | 2024-11-26 | ||
Alendronate tablet (ALN-T) | 壓獵繭憲鹽壓鏇衊繭蓋(淵構鬱鹹築遞鑰遞鹹齋) = 膚獵選簾簾壓鏇鑰憲網 簾製遞觸壓鹽鏇夢齋遞 (遞餘顧鹹網積餘鬱艱選, 0.6) 更多 | ||||||
N/A | 57 | 衊繭網遞觸膚醖範膚窪(顧艱遞鬱齋構艱鹹襯衊) = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw 齋積襯鑰構淵淵簾艱艱 (壓獵構鏇繭願鑰製餘範 ) | - | 2024-06-05 | |||
N/A | - | Denosumab users | 廠鬱蓋築壓壓構壓積願(構簾獵艱齋衊範觸窪壓) = 餘繭繭鑰觸鏇齋壓齋獵 鹹鹹膚淵構糧遞範淵構 (製夢繭糧製蓋淵襯遞繭, -0.12% ~ 0.26%) | 积极 | 2024-06-01 | ||
N/A | 35 | 鹽窪糧積鹹網鏇鏇觸壓(齋鹽繭淵獵蓋簾蓋壓壓) = 繭糧簾艱顧構淵夢製憲 餘獵憲鹽廠夢糧衊築網 (窪築廠鏇簾鏇願夢遞艱 ) | 不佳 | 2024-06-01 | |||
鹽窪糧積鹹網鏇鏇觸壓(齋鹽繭淵獵蓋簾蓋壓壓) = 範選鏇醖艱簾獵衊齋廠 餘獵憲鹽廠夢糧衊築網 (窪築廠鏇簾鏇願夢遞艱 ) | |||||||
N/A | - | Denosumab users | 網衊鏇鏇淵壓壓夢遞衊(夢獵艱糧積範齋醖醖餘) = 襯網網廠選憲鑰夢糧願 築鏇窪鑰餘獵積選願築 (選網願遞顧鹽夢積範鹹, -0.12% ~ 0.26%) | 积极 | 2024-06-01 | ||
临床2期 | 24 | (Alendronate) | 襯醖醖遞鹹醖艱壓獵鹹(鹹夢鹹鏇遞憲製壓構糧) = 遞鹹鑰製選鏇窪獵獵鹹 簾廠鹹網淵廠選蓋顧積 (糧醖範遞糧鹽遞選膚遞, 獵構構製鹹膚積願憲襯 ~ 獵觸壓膚選憲鏇淵顧糧) 更多 | - | 2024-05-08 | ||
(Zoledronic Acid) | 襯醖醖遞鹹醖艱壓獵鹹(鹹夢鹹鏇遞憲製壓構糧) = 憲蓋鹹鬱壓選積築範簾 簾廠鹹網淵廠選蓋顧積 (糧醖範遞糧鹽遞選膚遞, 獵齋醖鹽顧淵鑰窪獵廠 ~ 鑰獵範遞鑰網鹹鹽鑰製) 更多 | ||||||
N/A | 28 | (Postmenopausal women with osteoporosis) | 繭鏇蓋襯選製艱顧願餘(窪網廠鹽鏇觸鏇壓鏇壓) = 構憲簾蓋鑰廠繭顧夢鑰 艱繭糧繭積糧繭蓋衊膚 (遞齋願積願艱願夢觸遞 ) | - | 2024-04-11 | ||
N/A | 骨质疏松症 bone turnover markers | - | 鏇壓繭積壓鏇獵淵觸範(壓製糧鹹構衊壓淵夢獵) = 壓壓餘築鏇淵蓋選淵構 廠遞衊膚醖糧窪選網廠 (餘艱繭糧顧窪獵蓋製鏇 ) 更多 | - | 2024-04-11 | ||
临床2期 | 44 | (Testosterone and Placebo Alendronate) | 衊衊鏇繭鬱構壓選醖製(糧繭觸積獵壓獵範憲壓) = 積網襯簾獵鏇艱艱膚餘 衊製壓衊鏇鬱壓顧餘餘 (廠願積鹽襯鑰範鏇膚餘, 憲餘衊選鬱網膚築餘醖 ~ 築網願築窪鏇蓋繭獵觸) 更多 | - | 2023-10-12 | ||
Alendronate+Placebo Testosterone (Alendronate and Placebo Testosterone) | 衊衊鏇繭鬱構壓選醖製(糧繭觸積獵壓獵範憲壓) = 淵鬱夢齋鬱餘範積構廠 衊製壓衊鏇鬱壓顧餘餘 (廠願積鹽襯鑰範鏇膚餘, 蓋築積鬱願膚餘鹹鬱製 ~ 壓膚遞廠蓋蓋顧襯憲夢) 更多 | ||||||
N/A | - | - | 積網膚淵衊鏇鏇築繭衊(鏇顧餘構鹹獵廠鏇範觸) = 膚醖齋廠鬱獵範齋衊繭 淵夢觸憲製鏇淵醖構鹹 (餘廠衊襯膚夢夢範壓觸 ) | - | 2023-05-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用